Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Atara Biotherap 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 USA

www.atarabio.com Employees: 153 P: 805-623-4211

Sector:

Medical

Description:

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.

Key Statistics

Overview:

Market Capitalization, $K 126,827
Enterprise Value, $K 101,647
Shares Outstanding, K 7,210
Annual Sales, $ 128,940 K
Annual Net Income, $ -85,400 K
Last Quarter Sales, $ 3,450 K
Last Quarter Net Income, $ -4,300 K
EBIT, $ 26,230 K
EBITDA, $ 31,040 K
60-Month Beta -0.42
% of Insider Shareholders 4.00%
% of Institutional Shareholders 70.90%
Float, K 6,922
% Float 96.00%
Short Interest 165
Short Float 2.28%
Short Volume Ratio 0.23

Growth:

1-Year Return 31.96%
3-Year Return -78.55%
5-Year Return -96.42%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 91.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.32 on 11/12/25
Next Earnings Date 03/06/26
Earnings Per Share ttm 2.18
EPS Growth vs. Prev Qtr -268.42%
EPS Growth vs. Prev Year 89.08%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 06/20/24

ATRA Ratios

Ratio
Price/Earnings ttm 8.03
Price/Earnings forward 10.17
Price/Earnings to Growth N/A
Return-on-Equity % -41.78%
Return-on-Assets % 39.30%
Profit Margin % -66.23%
Debt/Equity 0.00
Price/Sales 0.98
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -5.22
Interest Coverage -17.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar